Thelansis

Late-Onset Pompe Disease Market Outlook Thelansis’s “Late-Onset Pompe Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Late-Onset Pompe Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s tra...

Late-Onset Pompe Disease Market Outlook Thelansis’s “Late-Onset Pompe Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Late-Onset Pompe Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Late-Onset Pompe Disease Overview Late-onset Pompe disease (LOPD, juvenile, and adult-onset) can appear as early as one year old and as late as the sixth decade. The late-onset form is associated with significant morbidity and is distinguished by progressive skeletal muscle weakness and respiratory insufficiency, eventually leading to respiratory failure and death. The late-onset form is variable, with all possible neuromuscular, m...

 Late-onset Pompe disease (LOPD, juvenile, and adult-onset) can appear as early as one year old and as late as the sixth decade. The late-onset form is associated with significant morbidity and is distinguished by progressive skeletal muscle weakness and respiratory insufficiency, eventually leading to respiratory failure and death. The late-onset form is variable, with all possible neuromuscular, musculoskeletal, respiratory, and cardiac symptoms. Muscle weakness is generally more pronounced in the proximal muscles of the lower extremities, with less involvement of the distal muscles and upper extremities. Muscle pathology can be asymmetric or symmetric; the trunk, thigh, and pelvic girdle muscles are the most likely to be affected, and specific muscle groups may be involved selectively. Patients may experience difficulty walking, running, participating in sports, climbing stairs, rising from a chair, or rising from a supine position. Motor development milestones are frequently mi...